The standardization of molecular diagnostics for myeloid diseases in Italy
Why is it important to risk stratify patients in CLL?
Final results of the AIM study of ibrutinib and venetoclax in mantle cell lymphoma
Minimal residual disease (MRD) monitoring for multiple myeloma is here to stay
Potential second-line treatment for indolent lymphoma